Consun Pharma FY26 H1 profit attributable to shareholders rises 19.5% to RMB 595.31 million; revenue increases 13.8% to RMB 1.78 billion

• Consun Pharmaceutical posted 1H 2026 profit attributable to equity shareholders of RMB 595.31 million, up 19.5% year over year.
• Revenue rose 13.8% to RMB 1.78 billion; basic EPS climbed 20.3% to RMB 0.71.
• Gross profit increased 20.1% to RMB 1.45 billion; gross margin widened 4.3 percentage points to 81.4%.
• Administrative expenses jumped 35.7% to RMB 241.01 million, driven by organizational optimization, talent hiring, and higher R&D spending.
• Board declared an interim dividend of HKD 0.38 per share, expected to be paid on or around Oct. 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Consun Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299525), on August 26, 2026, and is solely responsible for the information contained therein.